bluebird, Global Blood sink on SCD results

bluebird bio Inc. (NASDAQ:BLUE) sank $31.41 (38%) to $52.25 on Monday and Global Blood Therapeutics Inc. (NASDAQ:GBT) shed $11.74 (26%) to $33.93 after the companies presented data on their sickle cell disease products at the American Society of Hematology (ASH) meeting in Orlando,

bluebird's LentiGlobin BB305 gene therapy led to responses in sickle cell disease patients that were less robust than investors had hoped. ...